Literature DB >> 3517324

Neurofilament antibodies in systemic lupus erythematosus.

P Kurki, T Helve, D Dahl, I Virtanen.   

Abstract

Autoantibodies against neuronal antigens occur in sera of patients with systemic lupus erythematosus (SLE). These antibodies may have significance in the pathogenesis of neurological complications of SLE. However, the neuronal structures containing the corresponding autoantigens are poorly known. In our study we assayed circulating antibodies against defined neuronal components--neurofilaments--by an enzyme-linked immunosorbent assay (ELISA) using purified neurofilament polypeptides as targets. Circulating neurofilament antibodies (anti-NF) of IgG class were detected in 21% of 28 patients with SLE and in 6% of 17 patients with rheumatoid arthritis and in none of the 14 patients with primary sicca syndrome and 40 blood donors. The presence of anti-NF could also be confirmed by the indirect immunofluorescence technique using frozen sections of rat spinal cord. In one serum, anti-NF cross reacted with vimentin type of intermediate filaments. The antibodies bound both to the 70 kilodalton and the 200 kilodalton polypeptides of neurofilaments as judged by the immunoblotting technique. Two of 6 anti-NF positive patients had neurological complications.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3517324

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Antibodies to T- and L-isoforms of the cytoskeletal protein, fimbrin, in patients with systemic lupus erythematosus.

Authors:  E C De Mendonca Neto; A Kumar; N A Shadick; A M Michon; P Matsudaira; R B Eaton; P Kumar; P H Schur
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

2.  Brain-reactive autoantibody levels in the sera of ageing autoimmune mice.

Authors:  S A Hoffman; D N Arbogast; P M Ford; D W Shucard; R J Harbeck
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

3.  Screening test for rheumatic diseases: a combined enzyme immunoassay of rheumatoid factors and antibodies to DNA and extractable nuclear antigens.

Authors:  P Kurki; M Gripenberg; P Partanen; T Helve
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

4.  Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus.

Authors:  E S Husebye; Z M Sthoeger; M Dayan; H Zinger; D Elbirt; M Levite; E Mozes
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

5.  Antibodies to different isoforms of the heavy neurofilament protein (NF-H) in normal aging and Alzheimer's disease.

Authors:  L Soussan; K Tchernakov; O Bachar-Lavi; T Yuvan; E Wertman; D M Michaelson
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

6.  Very long charge runs in systemic lupus erythematosus-associated autoantigens.

Authors:  V Brendel; J Dohlman; B E Blaisdell; S Karlin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

7.  Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus.

Authors:  Sinah Engel; Simone Boedecker; Paul Marczynski; Stefan Bittner; Falk Steffen; Arndt Weinmann; Andreas Schwarting; Frauke Zipp; Julia Weinmann-Menke; Felix Luessi
Journal:  Ther Adv Neurol Disord       Date:  2021-10-22       Impact factor: 6.570

Review 8.  Hippocampal neurogenesis, depressive disorders, and antidepressant therapy.

Authors:  Eleni Paizanis; Michel Hamon; Laurence Lanfumey
Journal:  Neural Plast       Date:  2007       Impact factor: 3.599

9.  Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis.

Authors:  Soledad Matus; Patricia V Burgos; Marcela Bravo-Zehnder; Regine Kraft; Omar H Porras; Paula Farías; L Felipe Barros; Fernando Torrealba; Loreto Massardo; Sergio Jacobelli; Alfonso González
Journal:  J Exp Med       Date:  2007-12-03       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.